WARPTECHNEWS · LAB

Home AI Business Tech Archive

Storia: A Novel Pill For Cholesterol: FDA Approves Lipfendra — Warptech Lab News

WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

Home
Archivio
Editor's Brief
Cerca
Il tuo account
Newsletter tech/AI

Informazioni legali

Privacy Policy
Termini di servizio
Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Storia in 14 fonti

A Novel Pill For Cholesterol: FDA Approves Lipfendra

The FDA approved Lipfendra (enlicitide), the first oral PCSK9 inhibitor, on July 16, 2026.

Raccontata da

biopharmadive.com

medpagetoday.com

fiercepharma.com

oglobo.globo.com

economictimes.indiatimes.com

forbes.com+2 altre

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

forbes.comStai leggendo1 mese fa

A Novel Pill For Cholesterol: FDA Approves Lipfendra

The FDA approved Lipfendra (enlicitide), the first oral PCSK9 inhibitor, on July 16, 2026.

hindustantimes.com

Timeline cronologica

giovedì 16 luglio 2026·biopharmadive.com
Merck wins first approval of a PCSK9 cholesterol pill
The speedy clearance of Lipfendra is an important milestone for Merck and the result of a controversial voucher program put in place by former commissioner Marty Makary.
giovedì 16 luglio 2026·healio.com
FDA approves Lipfendra, the first oral PCSK9 inhibitor, to lower LDL
Merck and the FDA announced the approval of enlicitide 20 mg as an add-on to diet and exercise to lower LDL in adults with hypercholesterolemia and those with heterozygous…

1 mese fa

What do we know about the new cholesterol pill, Lipfendra? Merck's new once-a-day drug gets FDA nod

The FDA has approved Merck's once-daily cholesterol pill Lipfendra (enlicitide), marking the first oral PCSK9 inhibitor.

Leggi questa versione → originale

healio.com1 mese fa

FDA approves Lipfendra, the first oral PCSK9 inhibitor, to lower LDL

Merck and the FDA announced the approval of enlicitide 20 mg as an add-on to diet and exercise to lower LDL in adults with hypercholesterolemia and those with heterozygous familial hypercholesterolemia.Enlicitide…

Leggi questa versione → originale

nbcnews.com1 mese fa

FDA approves new kind of cholesterol pill

Merck’s pill, called Lipfendra, is a PCSK9 inhibitor, which works in a different way than a statin to lower cholesterol.

Leggi questa versione → originale

medpagetoday.com1 mese fa

FDA Approves First PCSK9 Inhibitor in Pill Form

With enlicitide, large LDL cholesterol reductions possible without a needle

Leggi questa versione → originale

economictimes.indiatimes.com1 mese fa

Merck gets US FDA nod for first-in-its-class oral cholesterol drug

The U.S. FDA has approved Merck's new cholesterol-lowering pill, Lipfendra. This oral medication works by blocking the PCSK9 protein, which helps lower bad cholesterol. Lipfendra offers an alternative for patients who…

Leggi questa versione → originale

giovedì 16 luglio 2026·

medpagetoday.com

FDA Approves First PCSK9 Inhibitor in Pill Form

With enlicitide, large LDL cholesterol reductions possible without a needle

giovedì 16 luglio 2026·

nbcnews.com

FDA approves new kind of cholesterol pill

Merck’s pill, called Lipfendra, is a PCSK9 inhibitor, which works in a different way than a statin to lower cholesterol.

giovedì 16 luglio 2026·

fiercepharma.com

Merck scores at FDA as Lipfendra becomes world's first oral PCSK9 treatment

Since reaching the market a decade ago, PCSK9 inhibitors have not lived up to their lofty expectations. | The FDA has approved Merck's internally developed cholesterol-lowering…

giovedì 16 luglio 2026·

oglobo.globo.com

EUA aprovam novo comprimido que reduz o colesterol ‘ruim’ em até 60%

É a primeira versão oral da classe de medicamentos inovadora chamada de inibidores de PCSK9, que amplia o tratamento do colesterol alto

giovedì 16 luglio 2026·

benzinga.com

FDA Approval Adds New Cholesterol Treatment Option in Merck Portfolio - Merck & Co (NYSE:MRK)

Merck's Lipfendra wins FDA approval as the first oral PCSK9 inhibitor for adults with high LDL cholesterol after positive Phase 3 results.

giovedì 16 luglio 2026·

economictimes.indiatimes.com

Merck gets US FDA nod for first-in-its-class oral cholesterol drug

The U.S. FDA has approved Merck's new cholesterol-lowering pill, Lipfendra. This oral medication works by blocking the PCSK9 protein, which helps lower bad cholesterol. Lipfendra…

giovedì 16 luglio 2026·

fortune.com

The cholesterol shot you couldn’t afford is now a pill | Fortune

The FDA has cleared Merck’s Lipfendra for patients whose artery‑clogging cholesterol remains high despite statins.

giovedì 16 luglio 2026·

upi.com

FDA approves first pill to significantly lower 'bad' cholesterol - UPI.com

The Food and Drug Administration on Thursday approved Merck's Lipfendra, which some have hailed as a breakthrough in cholesterol management.

giovedì 16 luglio 2026·

abcnews.com

FDA approves 1st-of-its-kind pill to reduce cholesterol

The Food and Drug Administration (FDA) approved on Thursday a first-of-its-kind oral option that can lower "bad" LDL cholesterol with a daily pill instead of a shot.

venerdì 17 luglio 2026·

forbes.com

A Novel Pill For Cholesterol: FDA Approves Lipfendra

The FDA approved Lipfendra (enlicitide), the first oral PCSK9 inhibitor, on July 16, 2026.

venerdì 17 luglio 2026·

ynetnews.com

FDA approves first cholesterol pill to match powerful injectable drugs

Merck’s once-daily Lipfendra offers a pill alternative to injectable cholesterol drugs after Phase 3 trials involving Israeli patients

sabato 18 luglio 2026·

hindustantimes.com

What do we know about the new cholesterol pill, Lipfendra? Merck's new once-a-day drug gets FDA nod

The FDA has approved Merck's once-daily cholesterol pill Lipfendra (enlicitide), marking the first oral PCSK9 inhibitor.